The biology and function of exosomes in cancer

Kalluri, Raghu

doi:10.1172/jci81135

Cited by 1,400 publications

(1,182 citation statements)

References 97 publications

Supporting

Mentioning

1,161

Contrasting

Unclassified

Order By: Relevance

“…The capacity of exosomes has spurred a renewed interest in their utility as a delivery system for various therapeutics (1)(2)(3)(4)(5)(6)(7)(8)(9)(10). Unlike liposomes and synthetic nanoparticles, the natural features of exosomes may offer unique advantages for the efficient delivery of therapeutic payloads into tumors.…”

Section: Introductionmentioning

confidence: 99%

Generation and testing of clinical-grade exosomes for pancreatic cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Generation and testing of clinical-grade exosomes for pancreatic cancer

et al. 2018

Self Cite

View full text Add to dashboard Cite

“…Emerging evidence suggests that exosomes, small EVs (40-150 nm) with a multivesicular endosomal origin secreted by both normal and neoplastic cells, play a crucial role in facilitating tumorigenesis (16). To prevent degradation in the circulation, miRNAs are released by cells in both exosomes and miRNA/protein complexes.…”

Section: Mirnas Packaged In Extracellular Vesicles (Evs)mentioning

confidence: 99%

Circulating microRNAs as emerging non-invasive biomarkers for gliomas

Santangelo¹,

Tamanini²,

Cabrini³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

No single circulating biomarker has been put to practice for malignant gliomas so far, the most lethal primary brain tumors. Many promising protein biomarkers such as the mutant EGFRvIII or glial fibrillary acidic protein (GFAP) have already been detected in the blood and cerebrospinal fluid (CSF) of patients with gliomas, but their clinical value is still pending validation. Furthermore, these and other proteins seem to lack sufficient sensitivity and specificity required for a successful biomarker in this clinical setting. The expression profiling of microRNAs (miRNAs) has already entered cancer clinics as diagnostic and prognostic biomarkers, for assessing tumor initiation, progression and response to treatment. Largescale miRNA expression analyses reported both up-regulation and down-regulation of several miRNAs in tumour tissues from patients with gliomas compared to normal brain tissue, thus supporting the development of miRNA-based biomarkers. Using comprehensive high-throughput approaches, such as microarrays, different circulating miRNAs were proposed as potential biomarkers of gliomas. This review is aimed to summarize the clinical evidence about circulating miRNA biomarkers discovered to date. Mandatory issues to develop clinically validated biomarkers to improve time of diagnosis, predicting response to treatment and prognosis of patients with gliomas are also herein addresses.

show abstract

“…Proteins that were more highly expressed in the MM secretome were more likely to be exosome proteins, but some proteins that had a lower protein expression in MM secretomes compared to mesothelial cell secretomes were also exosome proteins. Exosomes are extracellular, lipid bilayer, vesicles released by cells that contain cell derived protein, DNA and RNA (15) and there is now convincing evidence that they are important in many aspects associated with malignancy, including epithelial- (17) and MM-isolated exosomes enhance endothelial cell migration (4). A comparison of the highly expressed proteins compared to proteins that had a low expression suggests that MM cells rely on non-classical mechanisms such as exosomes to excrete many of those proteins that are relatively more abundantly expressed compared to normal mesothelial cells.…”

Section: Between-experiments Data Evaluation (A) Principal Componenmentioning

confidence: 99%